17th North American Regional ISSX Meeting (October 16

P242

A Novel Ring Oxidation of 4- or 5-Substituted 2(H)-Oxazole to Corresponding 2-Oxazolone Catalyzed by Cytosolic Aldehyde Oxidase
Vinod Arora, Bristol-Myers Squibb; Thomas Philip, Bristol-Myers Squibb; Xiaohua (Stella) Huang, Bristol-Myers Squibb; Yue-Zhong Shu, Bristol-Myers Squibb

P243

A Unique Metabolic Pathway of Sipoglitazar, a Novel Anti-Diabetic Agent: Cytochrome P450-Catalyzed Oxidation of Sipoglitazar Acyl Glucuronide and the Mutation Effect of the UGT2B15 Enzyme Responsible for Glucuronidation of Sipoglitazar
Mitsuhiro Nishihara, Takeda Pharmaceutical Company Limited; Yuto Hiura, Takeda Pharmaceutical Company Limited; Miyako Sudo, Takeda Pharmaceutical Company Limited; Naohiro Kawaguchi, Takeda Pharmaceutical Company Limited; Junzo Takahashi, Takeda Pharmaceutical Company Limited; Yutaka Kiyota, Takeda Pharmaceutical Company Limited; Takahiro Kondo, Takeda Pharmaceutical Company Limited; Satoru Asahi, Takeda Pharmaceutical Company Limited

P244

Assessment of pharmacokinetics using chimeric mice with humanized livers
Kristin Samuelsson, AstraZeneca; Kathryn Pickup, AstraZeneca; John Swales, AstraZeneca; James Yates, AstraZeneca; Christopher Smith, AstraZeneca; Richard Gallagher, AstraZeneca; Yoshio Morikawa, PhoenixBio Co., Ltd.; Ian Wilson, AstraZeneca

P245

Co-culture of Cryopreserved Primary Rat and Human Kupffer Cells and Hepatocytes to Study APAP Cytotoxicity
Rafal P. Witek, Life Technologies; Gemma L. Mendel, Life Technologies; Todd W. Stewart, Life Technologies; Kirsten B. Amaral, Life Technologies; Adam M. Farmer, Life Technologies; Rachel M. Witek, Life Technologies; Manda Edwards, Life Technologies; Kimberly Freeman, Life Technologies; Erica Deibert, Life Technologies; Brian J. Paszkiet, Life Technologies; Jonathan P. Jackson, Life Technologies; Stephen S. Ferguson, Life Technologies

P246

Comparison of Metabolism of Donepezil in Human, Following Oral and Dermal Administration, and in an In Vitro Model of Human Epidermis
Sandra Dennis, Charles River Laboratories; Renata Murgasova, Charles River Laboratories; Susan Meier-Davis, Teikoku Pharma USA, Inc

P247

Comparison of Novel Luciferin-1A2 Substrate and Phenacetin for Measuring CYP1A2 induction in Human Hepatocytes
Timothy A. Moeller, Celsis In Vitro Technologies; Dongping Ma, Promega Corporation; Stephen Dennel, Celsis In Vitro Technologies; James J. Cali, Promega Corporation

P248

Differences in biotransformation of raloxifen, tamoxifen and tamoxifen metabolites in Ishikawa human endometrial and MCF7 human breast cancer cell lines
Teresa Wilborn, McWhorter School of Pharmacy, Samford University; Erika Cretton-Scott, McWhorter School of Pharmacy, Samford University; Lori Coward, McWhorter School of Pharmacy, Samford University; Gregory Gorman, McWhorter School of Pharmacy, Samford University; Charles N. Falany, University of Alabama at Birmingham

P249

Evaluation of non-CYP mediated metabolism: Comparison of recombinant enzymes and sub-cellular fractions in identifying non-CYP mediated pathways
Philip J. Butler, Cyprotex; Katie Fox, Cyprotex; Michael Griffin, Cyprotex; Clive Dilworth, Cyprotex

P250

Human Metabolism of JWH-018 and JWH-073 and In Vitro Characterization of Major Omega and Omega-1 Metabolites
Krishna C. Chimalakonda, University of Arkansas for Medical Science; Lisa K. Brents, University of Arkansas for Medical Sciences; Cindy L. Moran, Arkansas State Crime Lab; Paul L. Prather, University of Arkansas for Medical Science; Laura P. James, Department of Pediatrics; Anna Radominska-Pandya, University of Arkansas for Medical Science; Jeffery H. Moran, AR Public Health Laboratory

P251

IDENTIFICATION OF THE HUMAN ENZYMES INVOLVED IN THE OXIDATIVE METABOLISM OF CRIZOTINIB
Theodore R. Johnson, Pfizer Inc.; Sue Zhou, Pfizer Inc.; Caroline A. Lee, Pfizer Inc.; Andrea Clouser-Roche, Pfizer Inc.; Sascha Freiwald, Pfizer Inc.; Kuresh A. Youdim, Pfizer Inc.; Karen Aherne, Pfizer Inc.; Minerva R. Batugo, Pfizer Inc.; Judith Skaptason, Janssen Pharmaceutical Company of Johnson & Johnson; Shinji Yamazaki, Pfizer Inc.; Michael R. Wester, Pfizer Inc.; Bill J. Smith, Pfizer Inc.

P252

Identification of Novel Phase I and Phase II Metabolites of Maraviroc Using Human Liver Microsomes
Yanhui Lu, The Johns Hopkins University, School of Medicine; Craig W. Hendrix, The Johns Hopkins University, School of Medicine; Namandje N. Bumpus, The Johns Hopkins University, School of Medicine

P254

Mechanistic studies on Nefazodone side chain cleavage using 18O2: A Baeyer-Villiger oxidation specifically catalyzed by CYP3A4 through a ferric peroxide intermediate
Amin Kamel, Novartis Institutes for Biomedical Research Inc.

P256

Oxidative Metabolism of 20(S)-Protopanaxadiol in Human Intestinal and Hepatic Microsomes
Nga Ting Colette Chiu, University of British Columbia; Subrata Deb, Vancouver Prostate Centre; Hans Adomat, Vancouver Prostate Centre; William Jia, University of British Columbia; Emma Guns, Vancouver Prostate Centre

P257

Oxidative Metabolism of a Methylsulfonyl Moiety
Nick Neitzel, Array BioPharma Inc.; Brian Baer, Array BioPharma Inc.; Brad Fell, Array BioPharma Inc.; Lance Williams, Array BioPharma Inc.; Ron Franklin, Array BioPharma Inc.

P258

Pharmacokinetics, Metabolism and Excretion of ¹⁴C-Monoethyl Phthalate (MEP) and ¹⁴C-Diethyl Phthalate (DEP) after Single Oral and IV Administration in the Juvenile Dog
Clair I. Smart, Huntingdon Life Sciences; L. M. Kao, Johnson and Johnson Pharmaceutical Research and Development, L.L.C.; Brian John, Huntingdon Life Sciences; Bruce Ruoff, Johson & Johnson Pharmaceutical Research and Development, L.L.C.; G. Mannens, Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica N.V.; N. Bower, Eisai Inc.; T. Aoki, Eisai Co., Ltd.

P259

Substrate Specificity for FMO- and CYP-Mediated Reactions and Enzyme Inactivation in HLM: Methyl p-Tolyl Sulfide Versus Benzydamine
Zhiming Wen, Absorption Systems LP; Robert Strab, Absorption Systems LP; Elizabeth Henry, Absorption Systems LP; Kenneth Roberts, Absorption Systems LP; Ramesh Bambal, Absorption Systems LP; Sid Bhoopathy, Absorption Systems LP; Albert Owens, Absorption Systems LP; Ismael Hidalgo, Absorption Systems LP

P260

Time-dependent Cytochrome P450-mediated Metabolism of Etravirine in Primary Human Hepatocytes
Lindsay Yanakakis, The Johns Hopkins University; Namandje N. Bumpus, The Johns Hopkins University, School of Medicine

P261

Using �Humanized' TK-NOG Mice to Predict Human Drug Metabolism and Drug-Drug Interactions
Yajing Hu, Stanford University; Toshi Nishimura, Stanford University; Manhong Wu, Stanford University; Hiroshi Suemizu, Central Institute for Experimental Animals; Menashe Elazar, Stanford University; Jeffrey Glenn, Stanford University; Masami Hasegawa, Central Institute for Experimental Animals; Masato Nakamura, Central Institute for Experimental Animals; Tatsuji Nomura, Central Institute for Experimental Animals; Yuan Chen, Genentech Inc.; Ming Zheng, Stanford University; William L. Fitch, Stanford University; Gary Peltz, Stanford University